Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | STAT3 | P40763 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | GABRE | P78334 | 1/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18730814 | 0.93 | STAT3 (0.52) | ALDH1A1STAT3MAPTLMNASMN1; SMN2 | |
| SCHEMBL17345532 | 0.92 | ALDH1A1 (0.53) | ALDH1A1STAT3MAPTLMNASMN1; SMN2 | |
| SCHEMBL18807113 | 0.90 | STAT3 (0.57) | ALDH1A1STAT3MAPTLMNASMN1; SMN2 | |
| SCHEMBL17345519 | 0.89 | STAT3 (0.53) | ALDH1A1STAT3MAPTLMNASMN1; SMN2 | |
| SCHEMBL18730823 | 0.89 | STAT3 (0.56) | ALDH1A1STAT3MAPTLMNASMN1; SMN2 | |
| SCHEMBL17345518 | 0.89 | ALDH1A1 (0.50) | ALDH1A1STAT3MAPTLMNASMN1; SMN2 | |
| SCHEMBL17345477 | 0.88 | STAT3 (0.64) | ALDH1A1STAT3MAPTLMNASMN1; SMN2 | |
| SCHEMBL18807118 | 0.88 | STAT3 (0.54) | ALDH1A1STAT3MAPTLMNASMN1; SMN2 | |
| SCHEMBL18691820 | 0.88 | STAT3 (0.57) | ALDH1A1STAT3MAPTLMNASMN1; SMN2 | |
| SCHEMBL17345553 | 0.88 | STAT3 (0.60) | ALDH1A1STAT3MAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267797-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-03-08 | — | — | US | disclosed |
| US-11267797-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-03-08 | — | — | US | disclosed |
| US-20200317630-A1 | ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| US-20200317630-A1 | ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| US-10689355-B2 | Anticancer agent | Kyoto Pharmaceuticals Industries, Ltd. (JP) | 2020-06-23 | — | — | US | disclosed |
| US-10689355-B2 | Anticancer agent | Kyoto Pharmaceuticals Industries, Ltd. (JP) | 2020-06-23 | — | — | US | disclosed |
| EP-3153508-B1 | NAPHTHOFURAN DERIVATIVES FOR USE AS ANTICANCER AGENTS | KYOTO PHARMA IND (JP) | 2020-03-18 | — | — | EP | disclosed |
| US-20190322636-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-20190322636-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-10377730-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-10377730-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-20180265489-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2018-09-20 | — | — | US | disclosed |
| US-10005752-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-10005752-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-10005752-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20170121299-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20170121299-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20170121299-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3153508-A1 | NOVEL ANTICANCER AGENT | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2017-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121299-A1 | NOVEL ANTICANCER AGENT | NTPCR, TP53, NME1 | ALDH1A1 187/4885STAT3 1231/4885MAPT 4391/4885 |
| US-20200317630-A1 | ANTICANCER AGENT | TP53, NTPCR, NQO1 | ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885 |
| US-10005752-B2 | Anticancer agent | TP53, NTPCR, NQO1 | ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885 |
| US-11267797-B2 | Anticancer agent | TP53, NTPCR, NQO1 | ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885 |
| US-20180265489-A1 | NOVEL ANTICANCER AGENT | NTPCR, TP53, NME1 | ALDH1A1 187/4885STAT3 1231/4885MAPT 4391/4885 |
| US-20190322636-A1 | NOVEL ANTICANCER AGENT | NTPCR, TP53, NME1 | ALDH1A1 187/4885STAT3 1231/4885MAPT 4391/4885 |
| US-10689355-B2 | Anticancer agent | TP53, NTPCR, NQO1 | ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885 |
| US-10377730-B2 | Anticancer agent | TP53, NTPCR, NQO1 | ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.